



To,
BSE Limited
P. J. Towers,
Dalal Street,
Mumbai – 400001

Date: 14.08.2024

Unit: Decipher Labs Limited (Scrip Code: 524752)

Sub: Outcome of Board Meeting for the quarter 30.06.2024 under regulation 30 and 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015.

Dear Sir/ Madam,

With reference to the subject cited, this is to inform the Exchange that the Board of Directors of **Decipher Labs Limited** at its meeting held on Wednesday, the 14th day of August, 2024 at 12.30 P.M. at registered office of the Company for the quarter ended 30.06.2024 considered and approved the following:

1. Un - Audited Financial Results (standalone and consolidated) for the quarter ended 30.06.2024. **(Attached)**. The **Consolidated** Financial figures in Rupees Lakhs in the 1st Quarter of the Year are summarized as below:

Consolidated Revenue	Profit Before Tax	Profit After Tax
744.10	135.80	94.66

2. Limited Review Report (standalone and consolidated) for the Quarter ended 30.06.2024. **(Attached)**
3. Appointment of M/s. S.S. Reddy & Associates, Company Secretaries as Secretarial Auditors for FY 2024-25. (Details annexed as **Annexure A**)
4. Appointment of Mr. Sushant Mohan Lal as Internal Auditor for FY 2024-25. (Details annexed as **Annexure A**)
5. Notice of the Annual General Meeting (AGM) and Directors Report for the financial year 2023-24.



DECIPHER
LABS LIMITED

Regd.Off: A-2, Q2, 5th Floor, Cyber Towers, Hitech City, Madhapur, Hyderabad, Telangana, India, 500081

Ph: (+91)-40-48536100 Url: www.decipherlabs.in Mail: decipherlabsltd@gmail.com
D.L.No.TG/15/04/2016-14766/14767 CINNo.L24230TG1986PLC006781 GST:36AAACC8372L1ZB

6. Annual General Meeting for the FY 2023-24 is scheduled to be held on Monday, 30.09.2024 at 11:00 a.m. through video conference or other audio-visual means.

The meeting concluded at 02:45 P.M.

This is for the information and records of the Exchange, please.

Thanking you.

Yours Faithfully

For Decipher Labs Limited

CHAPPIDI

SIVA KUMAR

REDDY

Digitally signed by
CHAPPIDI SIVA KUMAR

REDDY

Date: 2024.08.14

14:46:22 +05'30'

Siva Kumar Reddy Chappidi

Company Secretary and Compliance Officer

Encl. as above

Annexure A

[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with clause 7 of Para A of Annexure I of SEBI Circular dated July13, 2023]

Particulars	Internal Auditor	Secretarial Auditors
Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment of Mr. Sushant Mohan Lal as Internal Auditor of the company.	Appointment of M/s. S.S. Reddy Associates, Practicing Company Secretaries, as Secretarial Auditors of the Company.
Date of appointment & Terms of appointment	For the Financial Year 2024-25.	For the Financial Year 2024-25.
Brief Profile	Mr. Sushant Mohan Lal is an MBA from Kansas University, USA. He has been associated with the Company since long.	M/s. S.S. Reddy & Associates, established in the year 2007 by Mr. S. Sarveswara Reddy having wide client base ranging from Listed and Unlisted Companies in Infra and Real Estate, Defence, Software, Pharma etc., to Government Companies. Till date they have handled numerous corporate actions such as Initial Public Offers (IPOS), Takeovers, preferential issues, bonus issues, rights issues, buy back, mergers and demergers, delisting, revocation of suspension, corporate restructuring and so on.
Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable	Not Applicable

DECIPHER LABS LIMITED (CIN CL23230TG1986P LCO06781)

Regd.off: A-2, Q2, 5th Floor, Cyber Towers, Madhapur, Hyderabad, Telangana, India - 500081

URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-040-29323151

Statement of Unaudited Standalone Financial Results For the Quarter Ended 30th June, 2024

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Quarter ended			Year ended
	30.06.2024	31.03.2024	30.06.2023	31.03.2024
	Unaudited	Audited	Unaudited	Audited
I. Revenue from operations	38.34	335.67	-	353.16
II. Other income	0.17	0.50	0.50	1.99
III. Total Income (I + II)	38.51	336.17	0.50	355.14
IV. Expenses				
Purchase of Stock in trade	29.25	313.77	-	313.77
Changes in inventories of stock in trade	-	-	-	-
Employee Benefits Expense	7.72	4.25	4.25	16.99
Finance Costs	-	-	-	-
Depreciation expense	0.32	0.35	0.36	1.45
Other expenses	13.83	5.04	6.44	20.42
Total expenses	51.12	323.41	11.05	352.63
V. Profit/(Loss) before Exceptional items (III - IV)	(12.61)	12.75	(10.55)	2.51
VI. Exceptional items	-	-	-	-
VII. Profit/(Loss) after Exceptional items (V - VI)	(12.61)	12.75	(10.55)	2.51
VIII. Tax expense:				
(1) Current tax	-	-	-	-
(2) Deferred tax	0.47	(0.34)	(1.67)	(0.18)
IX. Profit/(Loss) for the period (VII-VIII)	(13.08)	13.10	(12.22)	2.33
X. Other comprehensive income	-	-	-	-
XI. Total comprehensive income for the year	(13.08)	13.10	(12.22)	2.33
Paid Up Equity Share Capital (FV of Rs 10 each)	1,010.00	1,010.00	1,010.00	1,010.00
XII. Earning per equity share				
(1) Basic	(0.13)	0.13	(0.12)	0.02
(2) Diluted	(0.13)	0.13	(0.12)	0.02

Notes

1. The operations of the Company relate to two segments viz; Manufacturing and Trading of Pharmaceutical drugs and Consultancy Services.

Segment information:

Particulars	Quarter ended			Year Ended
	30.06.2024	31.03.2024	30.06.2023	31.03.2024
	Unaudited	Audited	Unaudited	Audited
Segment Revenue				
a) Manufacturing and Trading of Pharmaceutical drugs	30.00	327.33	-	327.33
b) Consultancy Services	8.34	8.34	-	25.83
Total Sales	38.34	335.67	-	353.16
Less: Inter Segment Revenue	-	-	-	-
Total Revenue from Operations	38.34	335.67	-	353.16
Segment Result (Profit Before Tax and Interest from each Segment)				
a) Manufacturing and Trading of Pharmaceutical drugs	(9.87)	21.89	(10.55)	2.33
b) Consultancy Services	(2.74)	(9.15)	-	0.18
Total	(12.61)	12.74	(10.55)	2.52
Less: Interest and exceptional items	-	-	-	-
Total Profit before tax	(12.61)	12.74	(10.55)	2.52
Capital employed (Segment assets - segment liabilities)				
Segment assets				
a) Manufacturing and trading of Pharmaceutical drugs	900.13	1,267.85	886.72	1,267.85
b) Consultancy Services	8.34	8.25	-	8.25
Total Assets	908.47	1,276.10	886.72	1,276.10
Segment liabilities				
a) Manufacturing and trading of Pharmaceutical drugs	28.79	383.34	8.50	383.34
b) Consultancy Services	-	-	-	-
c) Unallocated liabilities	-	-	-	-
Total Liabilities	28.79	383.34	8.50	383.34

2. The above results for the quarter ended 30th June 2024 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 14th August 2024.

3. The financial results of the Company have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

For and on behalf of the Board



Sushant Mohan Lal

Sushant Mohan Lal
Executive Whole Time Director
DIN: 01227151

Place: Hyderabad
Date: 14th August 2024

Decipher Labs Limited (CIN CL23230TG1986PLC006781)

Regd.off: A-2, Q2, 5th Floor, Cyber Towers, Madhapur, Hyderabad, Telangana, India - 500081

URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040- 29323151

Statement of Unaudited Consolidated Financial Results For the Quarter Ended June 30, 2024

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Quarter Ended		Year Ended	
	30.06.2024	31.03.2024	30.06.2023	31.03.2024
	Unaudited	Audited	Unaudited	Audited
I. Revenue from operations	744.10	1,059.13	950.87	3,587.85
II. Other income	15.81	27.10	0.50	41.65
III. Total revenue (I + II)	759.91	1,086.23	951.37	3,629.51
IV. Expenses				
Purchase of Stock-in-Trade	29.25	313.77	-	313.77
Changes in inventories of finished goods and stock in trade	-	-	-	-
Employee benefits expense	511.35	540.22	804.83	2,774.94
Finance costs	-	21.24	0.52	21.76
Depreciation and amortisation expense	11.28	11.15	11.15	45.27
Other expenses	72.24	83.58	159.79	594.88
Total expenses	624.12	969.96	976.29	3,750.62
V. Profit/(Loss) before Exceptional item (III - IV)	135.80	116.27	(24.92)	(121.11)
VI. Exceptional items				
VII. Profit/(Loss) before tax (III - IV)	135.80	116.27	(24.92)	(121.11)
VIII. Tax expense:				
(1) Current tax	-	-	-	-
(2) Deferred tax	41.13	(4.22)	69.89	46.45
IX. Profit/(Loss) for the period (V-VI)	94.66	120.49	(94.81)	(167.56)
X. Other comprehensive income				
Items that will be reclassified to statement of profit and loss	-	-	-	-
Exchange differences on translating the financial statements of foreign Subsidiaries	(0.24)	4.75	2.23	32.77
XI. Total comprehensive income for the year	94.42	125.24	(92.58)	(134.79)
Net Profit/(Loss) for the year attributable to:				
Owners of the parent	94.66	120.49	(94.81)	(167.56)
Non-Controlling Interests	-	-	-	-
Other Comprehensive Income attributable to:				
Owners of the parent	94.42	125.24	(92.58)	(134.79)
Non-Controlling Interests	-	-	-	-
Total Comprehensive Income attributable to:				
Owners of the parent	94.42	125.24	(92.58)	(134.79)
Non-Controlling Interests	-	-	-	-
Paid Up Equity Share Capital (FV of Rs 10 each)	1,010.00	1,010.00	1,010.00	1,010.00
XI. Earning per equity share				
(1) Basic	0.94	1.19	(0.94)	(1.66)
(2) Diluted	0.94	1.19	(0.94)	(1.66)

Notes

1. The operations of the Group relate to two segments viz., Manufacturing and Trading of Pharmaceutical drugs and Consultancy Services.

Segment Information:

Particulars	Quarter Ended		Year Ended	
	30.06.2024	31.03.2024	30.06.2023	31.03.2024
	Unaudited	Audited	Unaudited	Audited
Segment Revenue				
a) Manufacturing and Trading of Pharmaceutical drugs	30.00	327.33	-	327.33
b) Consultancy Services	714.10	731.79	950.87	3,260.53
Total Sales	744.10	1,059.12	950.87	3,587.86
Less: Inter Segment Revenue	-	-	-	-
Total Revenue from Operations	744.10	1,059.12	950.87	3,587.86
Segment Result (Profit Before Tax and Interest from each Segment)				
a) Manufacturing and Trading of Pharmaceutical drugs	5.47	1.17	(10.55)	(9.06)
b) Consultancy Services	130.32	136.33	14.89	(90.29)
Total	135.80	137.51	4.34	(99.35)
Less: Interest and exceptional item	-	21.24	0.52	21.76
Total Profit/(Loss) before tax	135.80	116.27	3.82	(121.11)
Capital employed (Segment assets - segment liabilities)				
Segment assets				
a) Manufacturing and trading of Pharmaceutical drugs	900.47	427.85	46.72	427.85
b) Consultancy Services	2,207.76	2,935.46	2,565.18	2,935.46
Total Assets	3,108.22	3,363.31	2,611.90	3,363.31
Segment liabilities				

a) Manufacturing and trading of Pharmaceutical drugs	28.79	383.34	8.50	383.34
b) Consultancy Services	798.93	793.91	379.51	793.91
Total Liabilities	827.72	1,177.25	388.01	1,177.25

2. The above results for the quarter ended 30 June 2024 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 14th August 2024.
3. The financial results of the Group have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.
4. The above results as of 30 June 2024 include results of wholly owned subsidiary Decipher Software Solutions LLC, USA and step down subsidiary Decipher W.L.L., Bahrain.

For and on behalf of the Board



Sushant Mohan Lal
Executive Whole Time Director
DIN: 01227151



Place: Hyderabad
Date: 14th August 2024



Ramanatham & Rao
Chartered Accountants

P. B. No. 2102, Flat # 302, Kala Mansion,
Sarojini Devi Road, Secunderabad - 500 003
www.ramanathamand Rao.in
mail@ramanathamand Rao.in
ramanathamand Rao@gmail.com
040- 27814147, 27849305, 27840307

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Decipher labs Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Review Report to The Board of Directors
Decipher labs Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial Results of Decipher labs Limited ("the Holding Company") and its subsidiaries, (the Holding Company and its subsidiary together referred to as "the Group") for the quarter ended 30th June, 2024 ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The Statement includes the results of the subsidiaries.
Decipher Software Solutions LLC, USA
Decipher Soft Middle East W.L.L Bahrain
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the financial results of the subsidiary referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Ramanatham & Rao
Chartered Accountants

6. We did not review the interim financial results of one subsidiaries, Decipher Software Solutions LLC, USA and Decipher Soft Middle East W.L.L Bahrain included in the consolidated unaudited financial results whose interim financial results reflect total revenue of Rs.705.76 lakhs, total net profit after tax of Rs. 107.74 lakhs and total comprehensive Income of Rs.107.74 lakhs for the quarter ended 30th June, 2024, as considered in the consolidated unaudited financial results. These Interim financial results have been reviewed by other auditor whose report has been furnished to us by the Management and our conclusion on the consolidated financial results, in so far as it relates to the amounts and disclosure included in respect of this subsidiary is based solely on the report of such other auditor and the procedures performed by us are as stated in the paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matter.

For Ramanatham & Rao
Chartered accountants
(Firm Registration No.002934S)



K.Sreenivasan
Partner
Membership No.206421

UDIN: 24206421BKAKIW6339
Place : Secunderabad
Date : 14.08.2024





Ramanatham & Rao
Chartered Accountants

P. B. No. 2102, Flat # 302, Kala Mansion,
Sarojini Devi Road, Secunderabad - 500 003
www.ramanathamand Rao.in
mail@ramanathamand Rao.in
ramanathamand Rao@gmail.com
040- 27814147, 27849305, 27840307

**Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Decipher
labs Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015**

**Review Report to
The Board of Directors
Decipher labs Limited.**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Decipher labs Limited (the "Company") for the quarter ended 30th June 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ramanatham & Rao
Chartered accountants
(Firm Registration No.002934S)

K.Sreenivasan

Partner

Membership No.206421

UDIN: 24206421BKAKIV8083

Place: Secunderabad

Date : 14.08.2024

